Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Top 10 R&D spenders over the decade - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 17, 2003

    Top 10 R&D spenders over the decade

    Research and Development (R&D) expense is a vital ingredient for the growth of a company, as new products and innovations are the life-blood for sustaining the growth in any industry. Let us evaluate India Inc.’s scorecard on this count.

    Although India’s share is very miniscule, research and development has come a long way. More and more companies are making a conscious effort towards R&D. Some of the relative new entrants in the field of R&D include Telco, ONGC and IOC. All three have started to spend on R&D post FY95. So on an 8-year CAGR basis, IOC and ONGC’s R&D spending has increased by over 16% each, while Telco’s spending has increased at a mere 3%. But if one compares the R&D expense with sales then the ratio is not too enthusing.

    Top 10 R&D spenders
    Top R&D spenders FY02
    (Rs m) R&D exp. % of Sales
    Dr. Reddy'S Laboratories Ltd. 980 6.0%
    Tata Engineering & Locomotive Co. Ltd. 924 1.3%
    Reliance Industries Ltd. 901 0.2%
    Bharat Electronics Ltd. 896 4.7%
    Bharat Heavy Electricals Ltd. 871 1.3%
    Oil & Natural Gas Corpn. Ltd. 803 0.4%
    Ranbaxy Laboratories Ltd. 771 3.4%
    Mahindra & Mahindra Ltd. 690 2.1%
    Indian Oil Corpn. Ltd. 686 0.1%
    I T I Ltd. 581 2.6%

    The top spenders in R&D continue to be pharma companies. Dr. Reddy’s has been the top spender in FY02 (Rs 980 m) with a 53% CAGR over the last decade (6% of sales). In the top 50 R&D investors there are 13 pharma companies, 10 companies from the auto industry and 5 from the software industry. This clearly indicates that pharma companies continue to rule the roost on the Indian R&D front.

    Among auto companies, Telco is the top R&D investor (Rs 924 m), R&D as 1.3% of sales. Two-wheeler companies have also upped R&D spends significantly over the last few years. Bajaj Auto’s spends have clocked a 37% CAGR on R&D. For that matter, even TVS Motors has been spending at 39% CAGR. This indicates that the companies are spending more in order to roll out new models on a regular basis, which would help them in saving their turf and keep them ahead in the race for market dominance.

    Company Name Sales CAGR* R&D exp. CAGR*
    Dr. Reddy'S Laboratories Ltd. 28.9% 52.8%
    Tata Engineering & Locomotive Co. Ltd. 10.0% 3.4%**
    Reliance Industries Ltd. 33.8% 22.5%
    Bharat Electronics Ltd. 9.7% 15.3%
    Bharat Heavy Electricals Ltd. 7.7% 7.0%
    Oil & Natural Gas Corpn. Ltd. 14.8% 19.4%**
    Ranbaxy Laboratories Ltd. 17.8% 19.3%**
    Mahindra & Mahindra Ltd. 11.4% 40.0%
    Indian Oil Corpn. Ltd. 16.6% 18.2%**
    I T I Ltd. 6.8% 25.4%

    * CAGR FY92-FY02   ** CAGR FY95-FY02

    In FY02, Hero Honda was the market leader with 51% share and Bajaj Auto had a 23% market share in the motorcycle segment. But in FY02, Bajaj Auto’s R&D spending has been 1% of sales, as compared to 0.2% of sales for Hero Honda. Bajaj Auto probably has been forced to spend more to keep its dominance in the two-wheeler segment intact. Also, Hero Honda till date has had Honda’s support on the technical side. But the higher spending by Bajaj Auto has reflected in market share tally in FY03. During the fiscal, Hero Honda gave away market share and finished with 44% of the motorcycle pie, whereas Bajaj Auto gained share (albeit marginally) to 25%. Of course, there are a lot of other reasons for a company’s success, but R&D is the stepping-stone for keeping ahead in the race.

    Tough R&D spending as a percentage of sales maybe high (5%-6%) for pharma companies, when compared globally, in absolute terms it is very small. Glaxo spends around US$ 27 bn on R&D as compared to Dr. Reddy’s humble Rs 980 m. But atleast companies have realized the importance of investing in R&D. With globalization in full swing, domestic companies have to compete aggressively by way of innovative products and services. This can either come from internal spending and investment, or if the companies are not capable, they can bring in strategic partners to help them bridge this technological gap.



    Equitymaster requests your view! Post a comment on "Top 10 R&D spenders over the decade". Click here!


    More Views on News

    Tata Motors Ltd: Another Disappointing Quarter, Management fails to Perform! (Quarterly Results Update - Detailed)

    Aug 14, 2017

    Tata Motors Ltd disappoints again for both India and JLR business. Management commentary indicates a slow year ahead.

    Maruti Suzuki Ltd: Bumpy First Quarter. GST dents Margins! (Quarterly Results Update - Detailed)

    Aug 2, 2017

    GST realted cost impacts Margins, Management expects good year ahead.

    Hero Motocorp Ltd: Riding on the Scooters Growth, Maintains Margins! (Quarterly Results Update - Detailed)

    Aug 1, 2017

    Good Recovery in the Scooters market, expects pick up in exports too.

    Bajaj Auto Limited: Recovery in Exports but Domestic Disappoints! (Quarterly Results Update - Detailed)

    Aug 1, 2017

    New Export Markets picking up, Management expects good recovery in domestic Three wheeler market.

    Bajaj Auto Limited: Finishes the Year with Headwinds. Poised for a Recovery Ahead? (Quarterly Results Update - Detailed)

    Jul 6, 2017

    Ends the year on a Flat note. Expects good recovery in the exports market.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)